Your browser doesn't support javascript.
loading
Montrer: 20 | 50 | 100
Résultats 1 - 3 de 3
Filtre
Ajouter des filtres








Gamme d'année
1.
Indian J Physiol Pharmacol ; 2001 Jan; 45(1): 22-36
Article Dans Anglais | IMSEAR | ID: sea-107141

Résumé

Insulin resistance has emerged out as a concept linking diabetes mellitus and hypertension. Clinically it is characterized by hyperinsulinemia, hypertension, central obesity, abnormal lipid profile and cardiovascular complications. Insulin resistance is often associated with presence of anti-insulin antibodies and absent or dysfunctional insulin receptors. At molecular level insulin resistance appears to occur at the level of G-protein, kinase activation, glucose carriers (GLUT) and gene expression. Although with advent or research, the molecular mechanisms of insulin resistance are becoming more clear and there is development of new therapeutic agents like insulin sensitizers (thizolidinediones), in clinical practice, as of today, a patient with insulin resistance is looked upon as hypertensive or having diabetes mellitus. Accordingly he is taking either antihypertensives or antidiabetic drugs or both. It is thus essential to look into effects of these agents on insulin sensitivity. In recent years some scattered studies have been conducted to evaluate the effect of various antihypertensives and antidiabetics on insulin sensitivity. An antihypertensive or antidiabetic drug should directly benefit the cardiovascular risk profile of these patients. Although various newer approaches are explored to have a therapeutic benefit in insulin resistance, it is still a long way in the research, when a suitable pharmacological agent with least untoward effects will be available for the treatment of insulin residence.


Sujets)
Phosphatidylinositol 3-kinase/métabolisme , Animaux , Antienzymes/usage thérapeutique , Protéines G/métabolisme , Défaillance cardiaque/étiologie , Humains , Hyperglycémie/complications , Hypertension artérielle/étiologie , Hypoglycémiants/usage thérapeutique , Insulinorésistance/physiologie , Transporteurs de monosaccharides/métabolisme , Phosphotransferases/métabolisme , Transduction du signal/physiologie
2.
Indian J Physiol Pharmacol ; 1999 Apr; 43(2): 160-4
Article Dans Anglais | IMSEAR | ID: sea-107047

Résumé

Erectile dysfunction is a common and multi-factorial disease that strongly impairs the quality of life in men. During the past decade, many new therapeutic strategies have become available. But the need for oral treatment was strongly felt. This need appears to have been fulfilled with the introduction of sildenafil. The drug acts by enhancing smooth muscle relaxant effect of nitric oxide. A number of clinical studies have now proved its safety and efficacy. The drug has shaken social life all over the world and to accept this "magic pill" or not remains the question of individual choice.


Sujets)
Essais cliniques comme sujet , Interactions médicamenteuses , Dysfonctionnement érectile/traitement médicamenteux , Humains , Mâle , Monoxyde d'azote/métabolisme , Inhibiteurs de la phosphodiestérase/pharmacocinétique , Pipérazines/effets indésirables , Purines , Sulfones
3.
Indian J Exp Biol ; 1998 Dec; 36(12): 1273-5
Article Dans Anglais | IMSEAR | ID: sea-63016

Résumé

Cataleptic effect of pentazocine in mice was affected by pretreatment with dexfenfluramine, fluoxetine, buspirone, p-chlorophenylalanine, cyproheptadine, mianserin, cisapride, ondansetron, pindolol and propranolol. The results suggest that drugs which influence the activity of central serotonergic systems do modulate pentazocine-induced catalepsy in mice.


Sujets)
Animaux , Catalepsie/induit chimiquement , Interactions médicamenteuses , Mâle , Souris , Pentazocine/toxicité , Sérotonine/métabolisme , Agents sérotoninergiques/pharmacologie
SÉLECTION CITATIONS
Détails de la recherche